Interplay between negative symptoms, time spent doing nothing, and negative emotions in patients with schizophrenia spectrum disorders: results from a 37-site study
- PMID: 37735175
- PMCID: PMC10514038
- DOI: 10.1038/s41537-023-00372-x
Interplay between negative symptoms, time spent doing nothing, and negative emotions in patients with schizophrenia spectrum disorders: results from a 37-site study
Abstract
This study evaluated the relationship between negative symptoms, daily time use (productive/non-productive activities, PA/NPA), and negative emotions in schizophrenia-spectrum disorders (SSDs): 618 individuals with SSDs (311 residential care patients [RCPs], 307 outpatients) were surveyed about socio-demographic, clinical (BPRS, BNSS) and daily time use (paper-and-pencil Time Use Survey completed twice/week) characteristics. Among them 57 RCPs and 46 outpatients, matched to 112 healthy controls, also underwent ecological monitoring of emotions (8 times/day for a week) through Experience Sampling Method (ESM). RCPs spent significantly less time in PA than outpatients. Patients with more negative symptomatology spent more time in NPA and less in PA compared to patients with milder symptoms. Higher time spent in NPA was associated with negative emotions (p < 0.001 during workdays) even when correcting for BNSS total and antipsychotic polypharmacy (p = 0.002 for workdays, p = 0.006 for Sundays). Future studies are needed to explore in more detail the relationship between negative emotions, negative symptoms, time use, and functioning in individuals with SSDs, providing opportunities for more informed and personalised clinical treatment planning and research into interactions between different motivational, saliency and behavioural aspects in individuals with SSDs.
© 2023. Springer Nature Limited.
Conflict of interest statement
C.U.C. has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma, and Quantic. The other authors declare that they have no competing interests.
Figures
References
-
- Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch. Gen. Psychiatry. 1982;39:784–788. - PubMed
Grants and funding
- RF-2018-12365514/Ministero della Salute (Ministry of Health, Italy)
- RF-2018-12365514/Ministero della Salute (Ministry of Health, Italy)
- RF-2018-12365514/Ministero della Salute (Ministry of Health, Italy)
- RF-2018-12365514/Ministero della Salute (Ministry of Health, Italy)
- RF-2018-12365514/Ministero della Salute (Ministry of Health, Italy)
- RF-2018-12365514/Ministero della Salute (Ministry of Health, Italy)
- RF-2018-12365514/Ministero della Salute (Ministry of Health, Italy)
- RF-2018-12365514/Ministero della Salute (Ministry of Health, Italy)
- RF-2018-12365514/Ministero della Salute (Ministry of Health, Italy)
- RF-2018-12365514/Ministero della Salute (Ministry of Health, Italy)
LinkOut - more resources
Full Text Sources